Will sparsentan cause liver and kidney toxicity and safety analysis

Sparsentan () is a selective angiotensinII receptor antagonist and endothelin receptor antagonist (DUAL-ARB /ERA), mainly used to treat chronic kidney diseases such as primary IgA kidney disease and FSGS. Its mechanism of action reduces proteinuria and delays the decline of renal function through dual receptor blockade, thereby improving patients' renal outcomes. However, since drug metabolism and excretion involve the liver and kidney systems, its potential toxicity and safety still need to be concerned.

Clinical studies have shown that sparsentan can cause mild to moderate increases in liver function indicators, such as ALT, AST, total bilirubin and other mild abnormalities. In most patients, symptoms are reversible and resolve after discontinuation of the drug or dose adjustment. Severe liver injury may occur in rare cases, so liver function needs to be monitored regularly before use and during treatment, especially in patients with pre-existing liver disease or concomitant medications that may increase the risk of hepatotoxicity.

As a drug for the treatment of kidney disease, sparsentane has an overall protective effect on kidney function, but increased serum creatinine, decreased glomerular filtration rate, or electrolyte abnormalities may still occur. For patients with poor basic renal function or with progressive chronic kidney disease, renal function indicators should be strictly monitored, and dosage adjustments or intermittent medication should be made according to the situation to avoid potential nephrotoxicity.

In clinical application, sparsentan is generally well tolerated, but changes in liver and kidney function still need to be paid attention to. It is recommended that patients conduct a comprehensive liver and kidney function assessment before treatment, regularly review blood biochemical indicators during medication, and promptly adjust the dose or suspend medication when significant abnormalities occur. Through scientific monitoring and individualized management, sparsentan can reduce proteinuria and improve renal outcomes while minimizing the risk of liver and kidney toxicity, achieving safe and effective treatment results.

Reference materials:https://www.drugs.com/